11 Best Genomic Stocks to Buy Now

Published October 19, 2021 at 9:25 am EDT Updated August 31, 2026 at 11:54 am EDT

In this article, we will take a look at the 11 best genomic stocks to buy now.

Genomics is a branch of biology that studies the structure, function, evolution, mapping, and editing of genomes, which refer to the complete set of DNA of an organism, as opposed to genetics, which is the study of individual genes. With the rapid advancements in technology, it has become quite convenient to utilize genomes in detecting diseases and developing a well-informed diagnosis. With the COVID-19 pandemic affecting the global mortality rate, governments are realizing the importance of genomics now more than ever.

The first time genomics gained the interest of investors and governments was in 1990, when the Human Genome Project commenced. It took 13 years to reach fruition, and $2.7 billion dollars were spent on extensive research with the hope that mapping all the genes of the human genome would revolutionize healthcare and future standards of living.

Today, governments are once again taking a keen interest in genomics, which is why they are investing steadily in the research and the development of new technologies in the field of genomics.

In February 2019, Genome Canada received a funding of $22.7 million by the Canadian Minister of Science and Sport, as well as $33.4 million by provincial governments to sponsor 36 projects. These projects diligently work to improve the lives of Canadian citizens with the help of genomics-based technologies that Genome Canada specializes in.

Similarly, in September 2019, pharmaceutical companies partnered with health experts and scientists to study the sequence of the genetic code of 500,000 volunteers at the Stockport-based UK Biobank. The project had a budget allowance of $224 million and aimed to improve genomics research to target cancer, cardiovascular diseases, diabetes, arthritis, and dementia, among others. The goal of this project was to enhance preventative measures, improve diagnosis, and configure better treatments.

Lastly, the Indian Department of Biotechnology launched the “Genome India Project” in January 2020. The project’s objective was to build a reference genome by collecting genetic samples from 10,000 Indian volunteers. The Genome India Project focuses on precision health, unique genetic disorders and mutations, translational research, and the genetic epidemiology of complex diseases found in the Indian population.

Forecasts state that the global genomics market will reach $54.4 billion by 2025, up from $22.7 in 2020, suggesting a CAGR of 19% during the forecast years. The market for genomics will flourish because of the interest in this field of study by governments globally, the increasing cases of cancer and the widespread use of next generation sequencing in cancer research and treatments, new entrants in the genomics market, and the wider application of genomics due to advancing technology and higher education.

Some of the top genomic stocks include Illumina, Inc. (NASDAQ:ILMN), CRISPR Therapeutics AG (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA), and Natera, Inc. (NASDAQ:NTRA), among others discussed in detail below.

Photo by National Cancer Institute on Unsplash

Our Methodology

Let’s dive into the 11 best genomic stocks to buy now. We took into account hedge fund sentiments, analysts’ ratings, long-term growth potential, and fundamentals while choosing these stocks. The stocks are ranked based on their popularity amongst the hedge funds, which was determined by the number of hedge funds that chose to invest in the company as of the end of the second quarter.

Why should we pay attention to hedge fund sentiment while choosing stocks? Insider Monkey’s research was able to identify in advance a select group of hedge fund holdings that outperformed the S&P 500 ETFs by more than 86 percentage points since March 2017. Between March 2017 and July 2021, our monthly newsletter’s stock picks returned 186.1%, vs. 100.1% for the S&P 500 ETF (SPY). Our stock picks outperformed the market by more than 86 percentage points (see the details here). That’s why we believe hedge fund sentiment is an extremely useful indicator that investors should pay attention to. You can subscribe to our free newsletter on our homepage to receive our stories in your inbox.

Best Genomics Stocks to Buy Now

11. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Number of Hedge Fund Holders: 33

The eleventh stock on our list of the best genomics stocks to buy now is Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), which is a biopharmaceutical company that focuses on developing and commercializing therapeutics for genetic diseases. The Massachusetts-based company is well-known for its RNAi Therapeutics, which focuses on targeting the root of the genetic diseases rather than the symptoms.

Out of the 873 hedge funds tracked by Insider Monkey, 33 hedge funds held stakes in Alnylam Pharmaceuticals, Inc., worth over $1.02 billion at the end of the second quarter of 2021. This is compared to the same number of hedge funds in the previous quarter, with stakes amounting to $740 million.

On August 3, the company reported earnings per share of -$1.61, beating analysts’ consensus estimates of -$1.63 by $0.02. Alnylam Pharmaceuticals, Inc. announced actual revenue of $220.55 million, beating analysts’ estimates by $27.35 million.

On October 4, UBS analyst Esther Rajavelu upgraded Alnylam Pharmaceuticals, Inc. from Neutral to Buy, raising the price target to $215 from $141. She assigned the Buy rating due to the company’s potential growth prospects, strong fundamentals, realistically achievable CAGR, and growing diversity in its ranks.

Out of the hedge funds tracked by Insider Monkey, Kurt Von Emster’s VenBio Select Advisor is the largest stakeholder in Alnylam Pharmaceuticals, Inc., with 1 million shares amounting to $169.5 million.

Like Illumina, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., and Natera, Inc., Alnylam Pharmaceuticals, Inc. is one of the best genomic stocks to buy now.

10. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Number of Hedge Fund Holders: 34

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a well-known name in the healthcare industry, focusing on medical research and drug development. The company has research facilities and corporate offices in Cambridge, Massachusetts. Sarepta Therapeutics, Inc. was first incorporated as AntiVirals in 1980, and the name then changed to AVI BioPharma before becoming a publicly listed company. It was rebranded as Sarepta Therapeutics, Inc. in 2012. As of 2019, the company has two approved drugs and is traded as a Russell 1000 Component. Sarepta Therapeutics, Inc. ranks tenth on our list of the 11 best genomic stocks to buy now.

At the end of the second quarter of 2021, 34 hedge funds out of the 873 tracked by Insider Monkey held stakes amounting to $539.7 million in Sarepta Therapeutics, Inc., up from 33 in the previous quarter with stakes valuing at $526.9 million.

The company reported earnings per share of -$1.02 on August 4, surpassing analysts’ consensus estimates of -$1.25 by $0.23. The actual revenue for Sarepta Therapeutics, Inc. was $164.09 million, beating analysts’ estimates by $2.14 million.

Out of the hedge funds tracked by Insider Monkey, Kurt Von Emster’s VenBio Select Advisor is the largest stakeholder in Sarepta Therapeutics, Inc., with 2.4 million shares worth $186.5 million.

Artisan Mid Cap Fund, managed by Artisan Partners, explained their position on Sarepta Therapeutics, Inc. in their Q1 2021 investor letter. Here is what they had to say:

“We ended our campaign in Sarepta Therapeutics. Sarepta Therapeutics is a leader in Duchenne muscular dystrophy (DMD) drug development. Shares were pressured during the quarter amid a disappointing clinical trial outcome for its DMD gene therapy. We believe the odds of FDA approval for this therapy are lower and the timeline longer. Fortunately, we controlled for this risk by keeping this holding in the GardenSM. While Sarepta’s pipeline of gene therapies for neuromuscular disorders remains attractive, we exited our position given this setback. We believe CropSM holding Catalent is a better risk-adjusted way to participate in these opportunities. Catalent is a leader in gene therapy manufacturing and one of Sarepta’s key partners.”

9. CRISPR Therapeutics AG (NASDAQ:CRSP)

Number of Hedge Fund Holders: 34

CRISPR Therapeutics AG is a Swiss-American biotech company operating from Cambridge, Massachusetts, and is headquartered in Zug, Switzerland. The CRISPR gene-editing platform is being utilized to rapidly develop therapies that treat cancer, diabetes, and hemoglobinopathies, among other life threatening diseases. CRISPR Therapeutics AG ranks ninth on our list of the best genomic stocks to purchase.

At the end of the second quarter of 2021, 34 hedge funds in Insider Monkey’s database held stakes amounting to $1.76 billion in CRISPR Therapeutics AG, up from 27 in the previous quarter with stakes valuing at $1.4 billion.

The company reported earnings per share of $9.44 on July 29, beating estimates by $6.32. The actual revenue for CRISPR Therapeutics AG was $900.7 million, surpassing analysts’ estimates by $484.25 million.

Canaccord analyst Arlinda Lee maintained a Buy rating on CRISPR Therapeutics AG on August 16, raising the price target to $160 from $151. She assigned the rating keeping in mind the upcoming gene-editing programs and trials, which displayed a huge potential for success and would treat a range of life endangering diseases.

Out of the hedge funds tracked by Insider Monkey, Catherine Wood’s ARK Investment Management is the largest stakeholder in CRISPR Therapeutics AG, with 7.77 million shares worth over $1.25 billion.

CRISPR Therapeutics AG’s partnership with Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) allows it to gain the necessary funding for its clinical trials. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) allotted $900 million to CRISPR Therapeutics AG, which increased the total funding for trials to $2.6 billion. In return, the profit share for Vertex in the project increased from 50% to 60%, since they provide regular funding to keep the trials afloat.

8. Exact Sciences Corporation (NASDAQ:EXAS)

Number of Hedge Fund Holders: 35

The eighth stock on our list of the 11 best genomic stocks to buy now is Exact Sciences Corporation (NASDAQ:EXAS), which is a company specializing in molecular diagnostics that detect cancer in early stages. Founded in 1995 and headquartered in Wisconsin, Exact Sciences Corporation is traded as a Russell 1000 Component.

At the end of the second quarter of 2021, 35 hedge funds in Insider Monkey’s database held stakes worth over $2.37 billion in Exact Sciences Corporation, indicating the stock’s popularity with smart money. This is compared to 41 hedge funds in the previous quarter, with stakes amounting to $2.4 billion.

The company reported earnings per share of -$0.76 on July 28, missing analysts’ consensus estimates of -$0.72 by $0.04. The actual revenue for Exact Sciences Corporation was $434.82 million, beating estimates by $14.37 million.

On September 16, Exact Sciences Corporation announced that it would expand its sales force by hiring 400 employees. The additional expense will be covered by the reduced promotion fee paid to Pfizer Inc. (NYSE:PFE) after the terms of their sales agreement were renegotiated. Keeping in mind the improved future sales after this strategic maneuver, Canaccord analyst Kyle Mikson reiterated a Buy rating on Exact Sciences Corporation, raising the price target to $160 on July 29.

Catherine Wood’s ARK Investment Management is the largest stakeholder in Exact Sciences Corporation, with 10.7 million shares valued at $1.33 billion.

Like Illumina, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., and Natera, Inc., Exact Sciences Corporation is one of the best genomic stocks to buy now.

RiverPark Funds mentioned Exact Sciences Corporation in their Q2 2021 investor letter, and highlighted the company’s excellent efforts to increase its market opportunity by $40 billion. Here is what they said:

“Despite reporting better-than-expected first quarter revenue and EBITDA, EXAS shares were a top detractor on concerns about increasing competition, as Guardant Health presented positive data for a competing colorectal cancer (CRC) blood test. Positively for EXAS, the recommended age for CRC screening was expanded to include the 45-to-49-age population, adding roughly 20 million potential patients.

In the last year, Exact has pivoted from its single cancer screening tests (Cologuard for colon cancer and Oncotype for breast cancer) to multi-cancer screening through its Thrive acquisition, and to minimal residual disease and recurrence monitoring through its recently announced Ashion and Tardis acquisitions. Through this pivot, Exact has tripled its market opportunity from $20 billion to $60 billion.”

7. Agilent Technologies, Inc. (NYSE:A)

Number of Hedge Fund Holders: 39

Agilent Technologies, Inc. (NYSE:A) is a California-based company, founded in 1999 as a spin-off from Hewlett Packard Enterprise Company (NYSE:HPE). Agilent Technologies, Inc. concentrates its efforts in the food, pharmaceutical, chemicals, energy, and forensics sectors. The company provides a full range of technology platforms and lab management services to the clinical and diagnostics markets, which aid in genomics and cloning, among other clinical trials.

39 hedge funds in Insider Monkey’s database held stakes amounting to $3.89 billion in Agilent Technologies, Inc. at the end of the second quarter of 2021. This is compared to 42 hedge funds in the previous quarter, with stakes worth $3.46 billion.

The company reported earnings per share of $1.1 on August 17, beating analysts’ estimates of $0.99 by $0.11. The actual revenue for Agilent Technologies, Inc. was $1.59 billion, surpassing estimates by $44.17 million.

On September 17, Cowen analyst Doug Schenkel kept an Outperform rating on the shares of Agilent Technologies, Inc., raising the price target to $200 from $165. He was confident that the company would meet or perform better than the estimated targets, and the top to bottom growth for both short and long-term was confirmed by the company’s current fundamentals.

Agilent Technologies, Inc. announced a quarterly dividend on 19.4 cents per share of common stock which would be payable on October 27. The amount and time of dividends paid would be subject to approval from the board of directors.

Bill Ackman’s Pershing Square is the largest stakeholder in Agilent Technologies, Inc., with 11.6 million shares worth $1.72 billion.

Like Illumina, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., and Natera, Inc., Agilent Technologies, Inc. is one of the notable genomics stocks in the market.

Pershing Square Holdings, in their Q2 2021 investor letter, expressed their desire to hold the Agilent Technologies, Inc. stock, had they not needed the capital. Here is their entire statement regarding the company:

“Our large commitment to UMG required that we raise cash from the sale of one of our other investments. In light of the high quality of companies in our portfolio, this was a difficult decision to make. Ultimately, we chose to sell Agilent, as its current share price approached our conservative estimate of intrinsic value. If we did not need the capital, we would not have sold the stock.

Agilent has been a highly successful investment since our original purchase nearly two years ago, compounded by our additional investment in the company in the Covid market decline last year. Agilent’s stock price has increased 2.2 times since our initial purchase as a result of the company’s acceleration in revenue growth and profi tability.10 Agilent has been a critical supplier of technology and services to labs around the world fighting the Covid pandemic. The company’s management team led by Mike McMullen deserves enormous credit for the company’s success and for its important contribution to science and the fight against Covid for which we all should be extremely grateful.”

6. Bio-Rad Laboratories, Inc. (NYSE:BIO)

Number of Hedge Fund Holders: 41

The sixth stock on our list of the best genomic stocks to buy now is Bio-Rad Laboratories, Inc. (NYSE:BIO), which manufactures technological products for life science research and clinical diagnostics markets. The company utilizes cutting-edge technology to offer clinical information in the blood transfusion, diabetes monitoring, autoimmune, and contagious diseases testing markets to support diagnosis and treatment.

At the end of the second quarter of 2021, 41 hedge funds from Insider Monkey’s database held stakes amounting to $1.29 billion in Bio-Rad Laboratories, Inc..

On July 29, the company reported earnings per share of $3.54 for the second quarter of 2021, beating analysts’ estimates by $0.84. The actual revenue for Bio-Rad Laboratories, Inc. was $715.93 million, beating analysts’ estimates by $76.92 million.

On July 20, Wells Fargo maintained an Overweight rating on Bio-Rad Laboratories, Inc., raising the price target to $930.

Bio-Rad Laboratories, Inc. partnered with Seoul-based Seegene on June 30 for the clinical development and commercialization of molecular diagnostic products for infectious diseases. The diagnostic tests by Seegene would be available in the US markets upon approval from the FDA.

Paul Marshall and Ian Wace’s Marshall Wace LLP is the biggest shareholder in Bio-Rad Laboratories, Inc., with 435,099 shares amounting to $280.3 million.

5. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Number of Hedge Fund Holders: 41

Intellia Therapeutics, Inc. is the fifth stock on our list of the 10 best genomic stocks to buy now. The biotech company was founded in 2014 to create biopharmaceuticals using the CRISPR gene-editing system. In 2015, Intellia Therapeutics, Inc. partnered with Novartis AG (NYSE:NVS) to utilize CRISPR to create treatments for beta thalassemia and sickle cell disease.

41 out of 873 hedge funds tracked by Insider Monkey held stakes amounting to $2.28 billion in Intellia Therapeutics, Inc. at the end of the second quarter of 2021. This is compared to 29 hedge funds in the previous quarter with stakes valued at $1.13 billion.

On October 5, Guggenheim analyst Debjit Chattopadhyay initiated coverage of Intellia Therapeutics, Inc. with a Buy rating and raised the price target to $170.

The clinical trial application by Intellia Therapeutics, Inc. was approved by New Zealand Medicines and Medical Devices Safety Authority to initiate a study for treating adults with hereditary angioedema. This clinical trial would determine the correct dosage of NTLA-2002 for future studies.

Catherine Wood’s ARK Investment Management is the leading stakeholder in Intellia Therapeutics, Inc., with 7.68 million shares amounting to $1.24 billion.

In their Q2 2021 investor letter, Carillon Tower Advisers discussed their stance on Intellia Therapeutics, Inc.. Here is what they said:

“Intellia Therapeutics is a clinical-stage genome editing company focused on the development of proprietary, potentially curative therapeutics. The company’s stock soared after announcing positive interim data from an ongoing phase 1 clinical study of its in vivo gene editing candidate, which is being developed as a single-dose treatment for hereditary transthyretin (ATTR) amyloidosis. This specific form of therapy would be the first of its kind resulting in the precision editing of a gene in a target tissue in the human body.”

4. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Number of Hedge Fund Holders: 44

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is the fourth stock on our list of the 10 best genomic stocks to buy now. This is a California-based biotechnology company whose key research is focused on enzyme replacement therapies. As of 2016, BioMarin Pharmaceutical Inc. has marketed 6 orphan drugs, and is in the process of developing new therapies and medications. BioMarin Pharmaceutical Inc. is traded as a Russell 1000 Component.

At the end of the second quarter of 2021, 44 hedge funds in Insider Monkey’s database held stakes amounting to $1.32 billion in BioMarin Pharmaceutical Inc., up from 43 in the previous quarter with stakes worth over $1.26 billion.

Jefferies analyst Akash Tewari assumed coverage of BioMarin Pharmaceutical Inc. with a Buy rating, raising the price target to $100 on October 6. Tewari justified his rating to investors by stating the company would encash a $2.3 billion opportunity if its two key products, Roctavian and Voxzogo, are approved. He was optimistic about the FDA approval and subsequent profits.

Julian and Felix Baker’s Baker Bros. Advisors holds the largest stake in BioMarin Pharmaceutical Inc., with 7.58 million shares amounting to $633.2 million.

ClearBridge Investments mentioned the stock in their letter. Here is what they said in their Q1 2021 investor letter:

“The Strategy closed out of five positions (including BioMarin). We sold BioMarin Pharmaceutical after a number of its clinical catalysts had played out.”

3. Illumina, Inc. (NASDAQ:ILMN)

Number of Hedge Fund Holders: 51

Illumina, Inc. is the third stock on our list of the 10 best genomic stocks to purchase now. The American biotechnology company develops and sells integrated systems for studying genetic variation and biological function. The California-based Illumina, Inc. single handedly deployed a technology that reduced the cost of sequencing a human genome to $1000 in 2014 from $1 million in 2007.

At the end of the second quarter of 2021, 51 hedge funds in Insider Monkey’s database held stakes amounting to $1.97 billion in Illumina, Inc..

On September 20, Illumina, Inc. announced that it would open entities in Colombia and Mexico, which would not only focus on key healthcare systems and hospitals, but also support local and nearby Illumina, Inc. partners across Latin America, including countries in the Caribbean, Central American, and South America.

Out of the hedge funds tracked by Insider Monkey, GuardCap Asset Management is the largest stakeholder in Illumina, Inc., with 1.22 million shares amounting to $580.7 million.

In their Q2 2021 investor letter, RiverPark Funds declared Illumina, Inc. as the market leader in the genomics industry. Here is what they said:

“ILMN shares were our final top contributor for the quarter, rebounding from a decline in March due to the FTC filing a complaint to block the company’s acquisition of Grail. In April, Illumina reported better-than-expected results and a strong outlook. ILMN revenue grew 27%, with Sequencing revenue up 29%, instrument revenue up 123% and consumables up 26%. Adjusted operating margin grew sequentially to 32.1% from 20.9% in 4Q20, significantly exceeding estimates. Management also increased its full-year 2021 revenue growth guidance from its previous 17%-20% growth (we previously wrote we thought it to be conservative) to 25%-28%.

We continue to view the company’s core genomics industry as offering one of the larger total addressable markets that we cover, and ILMN is the clear innovation leader in sequencing and array-based solutions for genetic analysis. With less than 0.02% of humans having been sequenced and 99% of the variants discovered in the genome having not yet been deciphered, Illumina, at only $3.5 billion of TTM revenue, is still in its infancy in what is potentially a greater than $50 billion genetics analysis tools market opportunity. With Illumina’s recent entrance into the potentially even larger liquid biopsy market (early-stage cancer screening via blood samples) through its acquisition of Grail, the company has two large growth opportunities ahead.”

2. Natera, Inc. (NASDAQ:NTRA)

Number of Hedge Fund Holders: 52

Natera, Inc. is the second stock on our list of the 10 best genomic stocks to buy now. Natera, Inc. is a Texas-based genetic testing company that is dedicated to non-invasive cell-free DNA testing that primarily focuses on women’s health, cancer, and organ health. Natera, Inc. has accredited and certified laboratories in California and Texas. Founded in 2004, the company is now traded as a Russell 2000 Component.

Out of the 873 hedge funds tracked by Insider Monkey, 52 held stakes in Natera, Inc. at the end of the second quarter of 2021, worth $1.89 billion. This is compared to 41 hedge funds holding stakes amounting to $1.22 billion in the previous quarter.

On August 9, Piper Sandler analyst Steven Meh kept an Overweight rating on Natera, Inc., raising the price target to $160 from $155. Meh believed that the company was well-positioned for growth in the second half of 2021 and beyond, while stating that the ADLT award that was granted to Natera, Inc. ensures Medicare reimbursement for the years to come.

Out of the hedge funds tracked by Insider Monkey, Samuel Isaly’s OrbiMed Advisors is the largest stakeholder in Natera, Inc., with 2.05 million shares amounting to $233.6 million.

The investment management firm, Alger, included Natera, Inc. in their ‘Alger Small Cap Focus Fund’, and praised the company’s performance and its position as the market leader in the genetic diagnostics industry. Here is what they said about Natera, Inc. in their Q4 2020 investor letter:

“Natera is a leading provider of genetic diagnostics tests used in the large, underpenetrated reproductive medicine, oncology and organ transplant markets. Natera’s disruptive technology is augmented with software algorithms, bioinformatics and artificial intelligence to improve the detection of diseases and deliver clinically actionable information, thereby addressing significant unmet medical needs and ultimately saving lives. Natera is a highly innovative company that has consistently invested 20% of its revenue in research and development. Natera stock outperformed in the fourth quarter after the company reported stronger-than-expected financial results for the three-month period ended September 30, driven by strong test volume. After the two leading reproductive medicine societies in the U.S. issued a positive joint opinion that recommends non-invasive prenatal testing (NIPT) for all pregnancies in August. UnitedHealthcare and Aetna, who were the two large national payers that did not provide reimbursement for the service, finally adopted formal coverage of NIPT. This development increases Natera’s potential for generating both strong test volume growth and a higher average price per NIPT. In October, Natera introduced testing for colorectal cancer, which is the first monitoring test launched in the U.S. to detect minimal residual disease (MRD) or cancer recurrence in solid tumors. Natera is also working to obtain final Medicare coverage and reimbursement for at least one additional application of its Signatera test involving the results of various immunotherapy drugs for cancer treatment.”

1. Thermo Fisher Scientific Inc. (NYSE:TMO)

Number of Hedge Fund Holders: 87

Thermo Fisher Scientific Inc. (NYSE:TMO) ranks first on the list of the 10 best genomic stocks to buy now. Thermo Fisher Scientific Inc. is a Massachusetts-based provider of scientific instruments, reagents and consumables, and software services.

The company offers a variety of genomics solutions using cutting edge technology, such as next-generation sequencing, real-time PCR, Sanger sequencing, and microarrays. Thermo Fisher Scientific Inc.’s genomics solutions are focused on oncology, infectious diseases, reproductive health, and inherited diseases. The company was formed after Thermo Electron and Fisher Scientific were merged in 2006. Since then, the scientific giant has acquired many companies in the field including Life Technologies Corporation in 2013, Alfa Aesar in 2015, Affymetrix in 2016, FEI Company in 2017, and BD in 2018.

Thermo Fisher Scientific Inc. was granted emergency use authorization by the FDA to conduct tests that would alleviate the COVID-19 pandemic. The company is traded as a S&P 100 and S&P 500 Component.

At the end of the second quarter of 2021, 87 hedge funds tracked by Insider Monkey held stakes amounting to $7.39 billion in Thermo Fisher Scientific Inc., up from 79 in the previous quarter with stakes worth $6.25 billion.

The company reported earnings per share of $5.6 for the second quarter of 2021 on July 28, beating analysts’ consensus estimates by $0.13. The actual revenue for Thermo Fisher Scientific Inc. was $9.27 billion, beating estimates by $546.4 million.

Thermo Fisher Scientific Inc. announced on October 1 that it would open a new biologics production facility in Lengau, Switzerland, as part of its deal with CSL Limited (OTC:CSLLY). The facility will be completed in 2022, and will employ a workforce of 200. Initially, the facility will solely support the production of CSL Limited’s product for patients with hemophilia B, but it would later cater to other customers as well.

On September 23, Goldman Sachs analyst Matthew Sykes upgraded Thermo Fisher Scientific Inc. stock to Conviction Buy from Buy, raising the price target to $690 from $600. Skyes believes that the company has excellent potential for growth, and they are highly competitive in the industry.

Alexander Becker’s Codex Capital is the largest stakeholder in Thermo Fisher Scientific Inc., with 15,600 shares worth $7.87 billion.

In their Q2 2021 investor letter, ClearBridge Investments mentioned Thermo Fisher Scientific Inc., and how the stock turned their exposure to the healthcare sector from underweight to overweight. Here is what they said:

“Two additional names in the health care sector in the quarter, partially funded with a sale, made strong contributions and helped push our relative exposure to the sector from underweight to overweight. We added Thermo Fisher Scientific to increase our exposure to health care tools, which has been an attractive and core segment within health care. Thermo Fisher’s instruments are used to monitor and protect air, water, and food quality, and the company has strong long-term fundamentals, a top-tier management team and a diversified business.”

You can also take a look at Carl Icahn’s Stock Portfolio: Top 12 Picks and 10 Tech IPOs that Flopped.

Follow Insider Monkey on Twitter